Getting some media attention

So a short little mention of Cynata in the Herald Sun posted about 40 minutes ago.

'ANOTHER stock flying yesterday was regenerative medicine group Mesoblast on news that US company Celgene has grabbed almost 5 per cent and an option over some of its promising stem cell technology.

While Mesoblast moves to a buy in the dips after a big run, there are some smaller Aussie companies playing in the regenerative medicine space that are worth a look.

Cynata can now mass manufacture the sort of stem cells used by Mesoblast and Admedus’ heart patch is very promising.

Both speculative buys.'

Hope the message is going far and wide!